Sichuan Good Doctor Panxi Pharmaceutical Co. Ltd. has identified polypeptides reported to be useful for the treatment of inflammatory bowel disease, ulcerative colitis, and dysbacteriosis.
A new drug that inhibits the glutamate carboxypeptidase II (GCPII) enzyme could be used to treat inflammatory bowel disease (IBD), according to a new study in mice and human organoids. After decades of research trying to design GCPII inhibitors against neurological disorders, the new compound could be effective for another use.
Terns Pharmaceuticals Inc.’s unveiled positive top-line data from the phase IIa Duet study testing TERN-501, an oral thyroid hormone receptor-beta (THR-B) agonist, given as a monotherapy or in combination with TERN-101, a liver-distributed farnesoid X receptor agonist, for the treatment of nonalcoholic steatohepatitis (NASH).
With a phase II failure, Palisade Bio Inc. has decided to halt development into one of two indications for its only asset, LB-1148. The oral formulation of a broad-spectrum serine protease inhibitor missed the primary endpoint in the Profile study of reducing intra-abdominal adhesions after bowel resection. Palisade said the safety data and efficacy results no longer support further development of LB-1148 in the indication.
Cocrystal Pharma Inc. announced the company has selected its broad-spectrum 3CL protease inhibitor CDI-988 for development as a potential oral therapy for norovirus.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has described integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of gastroenteritis.
Ventyx Biosciences Inc. has identified 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of ulcerative colitis and pulmonary fibrosis.
Celloram Inc., the U.S. subsidiary of the Seoul, South Korea-based Medpacto Inc., signed a €160 million (US$175.88 million) licensing deal with Genfit SA to develop Celloram’s inflammasome inhibitor, CLM-022, for liver disease.
Celloram Inc. has signed a licensing agreement with Genfit SA to advance Celloram’s first-in-class inflammasome inhibitor, CLM-022. The agreement grants Genfit exclusive global rights to develop CLM-022 in liver disease indications.
Researchers from Hepagene Therapeutics Inc. have disclosed preclinical data for the novel FXR agonist HPG-1860, which is being developed for the treatment of nonalcoholic steatohepatitis (NASH).
RSS
